Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sectra and Philips reunite over PACS in Japan

This article was originally published in Clinica

Executive Summary

Swedish medical image management firm Sectra has rekindled a distribution deal with electronics giant Philips for its picture archiving and communications system (PACS) in Japan. The companies had previously worked on a global basis from 1997 until 2005 as part of a deal that saw Philips sell Sectra’s PACS products worldwide. This deal ended when Philips bought US-based PACS firm Stentor for $280m in cash (www.clinica.co.uk, 8 July 2005). The new deal will see Philips sell the product, called Sectra PACS, in Japan under a joint branding policy. According to Linköping-based Sectra, there is still an installed base of around 30 Sectra/Philips PACS systems in Japan from the firms’ previous collaboration. The firm said these systems would act as a “platform and reference for future expansion in the quality-focused and demanding Japanese market”.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT077181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel